Abbott Laboratories (Pakistan) Limited Stock price

Equities

ABOT

PK0025701019

Pharmaceuticals

End-of-day quote Pakistan S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
452.2 PKR +0.78% Intraday chart for Abbott Laboratories (Pakistan) Limited -0.62% -1.74%
Sales 2021 42.57B 153M Sales 2022 49.26B 177M Capitalization 45.36B 163M
Net income 2021 5.97B 21.46M Net income 2022 3B 10.8M EV / Sales 2021 1.45 x
Net cash position 2021 8.38B 30.12M Net cash position 2022 8.54B 30.73M EV / Sales 2022 0.75 x
P/E ratio 2021
11.8 x
P/E ratio 2022
15.1 x
Employees 1,463
Yield 2021
5.57%
Yield 2022
3.24%
Free-Float 18.55%
More Fundamentals * Assessed data
Dynamic Chart
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Abbott Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Abbott Laboratories Announces Board Changes CI
Abbott Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Abbott Laboratories Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
1 day+0.78%
1 week-0.62%
Current month-4.45%
1 month-6.18%
3 months+0.49%
6 months+30.69%
Current year-1.74%
More quotes
1 week
440.00
Extreme 440
465.00
1 month
440.00
Extreme 440
483.00
Current year
399.99
Extreme 399.99
514.00
1 year
330.00
Extreme 330
514.00
3 years
330.00
Extreme 330
820.00
5 years
302.10
Extreme 302.1
820.00
10 years
302.10
Extreme 302.1
1 145.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 09-02-28
Director of Finance/CFO - 20-01-15
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman - -
Chief Executive Officer - 09-02-28
Director/Board Member - -
More insiders
Date Price Change Volume
24-03-27 452.2 +0.78% 6,100
24-03-26 448.7 +1.47% 1,100
24-03-25 442.2 -1.52% 1,100
24-03-22 449 -0.33% 200
24-03-21 450.5 -0.99% 700

End-of-day quote Pakistan S.E., March 26, 2024

More quotes
Abbott Laboratories (Pakistan) Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
More about the company
  1. Stock
  2. Equities
  3. Stock Abbott Laboratories (Pakistan) Limited - Pakistan S.E.